| Cubicin (daptomycin) / Merck (MSD) |
NCT00296049: Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy |
|
|
| Withdrawn | N/A | 0 | US | daptomycin, vancomycin | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Infection, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific | 03/06 | 03/06 | | |
NCT01212601: Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice |
|
|
| Completed | N/A | 203 | RoW | | AstraZeneca | S. Aureus Bloodstream Infection | 11/12 | 11/12 | | |
NCT01551719: Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation |
|
|
| Withdrawn | N/A | 0 | Europe | Implemented procedure, MIC/Breakpoint ratio and tissue penetration for available antibiotics e.g., - Semisynthetic Penicillins, - Cephalosporins, - Linezolid, - Vancomycin, - Daptomycin, - Teicoplanin, - Tigecycline | Federico II University | Infection of Skin and/or Subcutaneous Tissue | 03/13 | 03/13 | | |
NCT01219114: Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use |
|
|
| Withdrawn | N/A | 200 | RoW | | AstraZeneca | Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis | 10/13 | 11/13 | | |
NCT01012089: Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease |
|
|
| Completed | N/A | 6 | US | Daptomycin, Cubicin | University of Oklahoma, Cubist Pharmaceuticals LLC | Chronic Kidney Disease, Bacterial Infection | 04/14 | 04/14 | | |
DAPTODP, NCT02000414: Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection |
|
|
| Completed | N/A | 8 | Europe | intraperitoneal daptomycin | University Hospital, Caen | Peritoneal Infection | 12/17 | 12/17 | | |
